Skip to main content

Table 2 Univariate analyses of factors associated with OS and DFS in all surgical patients

From: Clinical efficacy of liver resection after downsizing systemic chemotherapy for initially unresectable liver metastases

  OS DFS
  HR 95 % CI p HR 95 % CI p
Age >65 years 5.12 2.34–11.9 <0.001 1.37 0.80–2.33 0.241
Male 1.87 0.89–4.31 0.100 1.18 0.70–2.04 0.538
Synchronous disease 2.45 1.14–5.85 0.021 1.50 0.87–2.65 0.141
Conversion disease 1.56 0.36–4.75 0.504 1.99 1.02–3.70 0.0435
Node-positive primary tumor 1.43 0.67–2.99 0.342 1.30 0.77–2.26 0.333
Rectum 0.83 0.37–1.74 0.897 1.11 0.71–1.92 0.709
Adjuvant chemotherapy 0.78 0.36–1.61 0.506 0.90 0.50–1.53 0.693
No. of liver metastases ≥5 1.43 0.63–3.06 0.164 2.18 1.23–3.79 0.0076
Maximum tumor size >5 cm 1.32 0.48–3.15 0.555 1.99 1.04–3.56 0.0375
CA19-9 ≥100 U/mL 1.40 0.55–3.13 0.457 1.46 0.77–2.63 0.235
R1 resection 1.07 0.51–2.17 0.853 1.15 0.68–1.96 0.597
  1. OS overall survival, DFS disease-free survival, HR hazard ratio, CI confidence interval